- Home
- WATT vs BCDA Comparison
WATT vs BCDA Comparison
Compare WATT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- BCDA
- Stock Information
- Founded
- WATT 2012
- BCDA N/A
- Country
- WATT United States
- BCDA United States
- Employees
- WATT N/A
- BCDA N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- BCDA Health Care
- Exchange
- WATT Nasdaq
- BCDA Nasdaq
- Market Cap
- WATT 9.1M
- BCDA 9.4M
- IPO Year
- WATT 2014
- BCDA N/A
- Fundamental
- Price
- WATT $0.31
- BCDA $2.27
- Analyst Decision
- WATT Strong Buy
- BCDA Strong Buy
- Analyst Count
- WATT 2
- BCDA 1
- Target Price
- WATT $2.25
- BCDA $25.00
- AVG Volume (30 Days)
- WATT 603.9K
- BCDA 94.4K
- Earning Date
- WATT 05-13-2025
- BCDA 03-26-2025
- Dividend Yield
- WATT N/A
- BCDA N/A
- EPS Growth
- WATT N/A
- BCDA N/A
- EPS
- WATT N/A
- BCDA N/A
- Revenue
- WATT $768,000.00
- BCDA $58,000.00
- Revenue This Year
- WATT $1,028.91
- BCDA N/A
- Revenue Next Year
- WATT N/A
- BCDA N/A
- P/E Ratio
- WATT N/A
- BCDA N/A
- Revenue Growth
- WATT 62.02
- BCDA N/A
- 52 Week Low
- WATT $0.26
- BCDA $1.63
- 52 Week High
- WATT $2.70
- BCDA $6.15
- Technical
- Relative Strength Index (RSI)
- WATT 45.03
- BCDA 42.76
- Support Level
- WATT $0.26
- BCDA $2.45
- Resistance Level
- WATT $0.31
- BCDA $2.95
- Average True Range (ATR)
- WATT 0.03
- BCDA 0.23
- MACD
- WATT 0.00
- BCDA -0.04
- Stochastic Oscillator
- WATT 44.55
- BCDA 20.92
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).